A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

Keyphrases

• Ancestral Strain 18%
• Anti-SARS-CoV-2 36%
• Booster Dose 100%
• Brazil 9%
• CD41 T Cells 18%
• Chile 18%
• Chilean 9%
• China 9%
• CoronaVac 100%
• COVID-19 18%
• Delta Variant of Concern 100%
• Emergency Department Use 9%
• Healthy Volunteers 9%
• Homologous Vaccination 9%
• Immune Response 36%
• Immunogenicity 18%
• Inactivated SARS-CoV-2 Vaccine 9%
• Inactivated Vaccine 9%
• Interferon-γ 9%
• Neutralization Activity 9%
• Neutralizing Antibodies 100%
• Omicron Variant of Concern 100%
• Phase III Clinical Trial 18%
• SARS-CoV-2-specific T Cells 9%
• Second Dose 18%
• Specific T Cells 9%
• T Cell Activation 18%
• T Cell Response 9%
• T Cells 100%
• Third Dose 9%
• Turkey 9%
• Two-dose 45%
• Vaccination Schedule 9%
• Variants of Concern 54%
• World Health Organization 18%

Immunology and Microbiology

• Booster Dose 100%
• Immune Response 36%
• Immunogenicity 18%
• Inactivated Vaccine 9%
• Interferon Gamma 9%
• Neutralization 9%
• Neutralizing Antibody 100%
• Normal Human 9%
• Omicron Coronavirus Variant 100%
• Secretion (Process) 9%
• Severe Acute Respiratory Syndrome Coronavirus 2 72%
• T Cell 100%
• T Cell Activation 18%
• Vaccination Schedule 9%
• Vaccine Efficacy 27%